» Articles » PMID: 26497752

Profile of Differentially Expressed MiRNAs in High-grade Serous Carcinoma and Clear Cell Ovarian Carcinoma, and the Expression of MiR-510 in Ovarian Carcinoma

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2015 Oct 27
PMID 26497752
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Improved insight into the molecular and genetic profile of different types of epithelial ovarian cancer (EOC) is required for understanding the carcinogenesis of EOC and may potentially be exploited by future targeted therapies. The aim of the present study was to identify a unique microRNA (miRNA) patterns and key miRNAs, which may assist in predicting progression and prognosis in high‑grade serous carcinoma (HGSC) and clear cell carcinoma (CCC). To identify unique miRNA patterns associated with HGSC and CCC, a miRNA microarray was performed using Chinese tumor bank specimens of patients with HGSC or CCC in a retrospective analysis. The expression levels of four deregulated miRNAs were further validated using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in an external cohort of 42 cases of HGSC and 36 cases of CCC. Kaplan‑Meier analysis was performed to analyze the correlation between the expression levels of the four miRNAs and patient prognosis. Among these validated miRNAs, miR‑510 was further examined in another cohort of normal ovarian tissues, as well as the HGSC, low‑grade serous carcinoma (LGSC) and CCC specimens using RT‑qPCR and in situ hybridization. The results revealed that, of the 768 miRNAs analyzed in the microarray, 33 and 50 miRNAs were significantly upregulated and downregulated, respectively, with at least a 2‑fold difference in HGSC, compared with CCC. The quantitative analysis demonstrated that miR‑510 and miR‑129‑3p were significantly downregulated, and that miR‑483‑5p and miR‑miR‑449a were significantly upregulated in CCC, compared with HGSC (P<0.05), which was consistent with the microarray results. Kaplan‑Meier analysis revealed low expression levels of miR‑510 and low expression levels of miR‑129‑3p, advanced International Federation of Gynecology and Obstetrics (FIGO) stage, lymphatic metastasis and that HGSC was significantly associated with the poorer overall survival rates (P<0.05). The expression of miR‑510 was significantly higher in the LGSC and CCC tissues, compared with the HGSC and normal ovarian tissues. The results of the present study suggested that different subtypes of EOC have specific miRNA signatures, and that miR‑510 may be involved differently in HGSC and CCC. Thus, miR‑510 and miR‑129‑3p may be considered as potential novel candidate clinical biomarkers for predicting the outcome of EOC.

Citing Articles

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.


The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment.

Davies M, Davey M, Miller N Genes (Basel). 2022; 13(11).

PMID: 36360295 PMC: 9690044. DOI: 10.3390/genes13112054.


Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Kandettu A, Adiga D, Devi V, Suresh P, Chakrabarty S, Radhakrishnan R Genes Dis. 2022; 9(6):1443-1465.

PMID: 36157483 PMC: 9485269. DOI: 10.1016/j.gendis.2021.12.026.


Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Liu S, Wu M, Wang F J Cancer. 2021; 12(13):3976-3996.

PMID: 34093804 PMC: 8176232. DOI: 10.7150/jca.47695.


Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.

Zhu C, Xu Z, Zhang T, Qian L, Xiao W, Wei H J Cancer. 2021; 12(8):2295-2316.

PMID: 33758607 PMC: 7974897. DOI: 10.7150/jca.53395.


References
1.
Streicher K, Zhu W, Lehmann K, Georgantas R, Morehouse C, Brohawn P . A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2011; 31(12):1558-70. DOI: 10.1038/onc.2011.345. View

2.
Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P . Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget. 2012; 2(12):1265-78. PMC: 3282083. DOI: 10.18632/oncotarget.401. View

3.
Zhao J, Liu C, Zhao H, Ding Y, Bi T, Wang B . Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research. Methods. 2012; 58(2):156-63. DOI: 10.1016/j.ymeth.2012.07.023. View

4.
Eitan R, Kushnir M, Lithwick-Yanai G, David M, Hoshen M, Glezerman M . Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol. 2009; 114(2):253-9. DOI: 10.1016/j.ygyno.2009.04.024. View

5.
Oom A, Humphries B, Yang C . MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014; 2014:959461. PMC: 4101974. DOI: 10.1155/2014/959461. View